SUPN Valuation

Supernus Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

32.220

+0.870(+2.780%)

Overview
Forecast
Valuation

SUPN Relative Valuation

SUPN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SUPN is overvalued; if below, it's undervalued.

Historical Valuation

Supernus Pharmaceuticals Inc (SUPN) is now in the Fair zone, suggesting that its current forward PE ratio of 16.27 is considered Fairly compared with the five-year average of 21.41. The fair price of Supernus Pharmaceuticals Inc (SUPN) is between 30.33 to 49.19 according to relative valuation methord.

Relative Value

Fair Zone

30.33-49.19

Current Price：32.22

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

1.73

P/B

Median3y

1.92

Median5y

1.92

9.79

FCF Yield

Median3y

7.17

Median5y

8.21

Competitors Valuation Multiple

The average P/S ratio for SUPN's competitors is 55.54, providing a benchmark for relative valuation. Supernus Pharmaceuticals Inc Corp (SUPN) exhibits a P/S ratio of 2.80, which is -94.96% above the industry average. Given its robust revenue growth of 5.99%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

SUPN.O

Supernus Pharmaceuticals Inc

2.80

Average P/S: 55.54

5.99%